Rheumatoid arthritis and systemic lupus erythematosus as immune complex diseases

Bulletin of the NYU Hospital for Joint Diseases

Volumn 67, Issue 3, 2009, Pages 251-253

  Weissmann, Gerald ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; RHEUMATOID FACTOR;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; BLOOD VESSEL; HUMAN; IMMUNE COMPLEX DISEASE; INFLAMMATION; KIDNEY; LUNG DISEASE; MOUTH FLORA; PHAGOCYTE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, NUCLEAR; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; COMPLEMENT ACTIVATION; HUMANS; IMMUNE COMPLEX DISEASES; IMMUNITY, INNATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEPTIDES, CYCLIC; PHAGOCYTES; SIGNAL TRANSDUCTION;

EID: 70350155425     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. Hargraves MM, Richmond H, Morton R. Presentation of 2 bone marrow elements, the tart cell and the L.E. cell. Proc Staff Meet Mayo Clin. 1948;23:25-28
2. Rose HM, Ragan C, Pearce E, et al. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with Rheumatoid Arthritis. Proc Soc Exp Biol Med. 1948;68:1-6.
3. Ward PA, Zvaifler NJ. Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest. 1971;50:606-616
4. Laurence, WA. Aid in rheumatoid arthritis is promised by new hormone. New York Times. April 21, 1949:1.
5. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17 hydroxy-11 dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. (Preliminary report). Proc Staff Meet Mayo Clin. 1949;24:181-297
6. Nobel Foundation. The Nobel Prize page. The Nobel Prize in Physiology or Medicine 1950. Available at http://www.nobel.se/medicine/laureates/1950. Accessed July 23, 2009.
7. Hollander JL, McCarty DJ, Astorga G, et al. Studies on the pathogenesis of rheumatoid joint inflammation. I. The "R.A. cell" and a working hypothesis. Ann Intern Med. 1965;62:271-280
8. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. (2000;43:1831-5.
9. Pope RM, Teller DC, Mannik M. The molecular basis of self-association of antibodies to IgG (rheumatoid factors) in rheumatoid arthritis. Proc Natl Acad Sci U S A. (1974;71:517-21.
10. Atkinson JP. Complement activation and complement receptors in systemic lupus erythematosus. Springer Semin Immunopathol. 1986;9:179-194
11. Belmont HM, Hopkins P, Edelson HS, et al. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum. (1986;29:1085-9.
12. Davies KA, Schifferli JA, Walport MJ. Complement deficiency and immune complex disease. Springer Semin Immunopathol. (1994;115:397-416.
13. Weissmann G, Zurier RB, Spieler PJ, et al. Mechanisms of lysosomal enzyme release from leukocytes exposed to immune complexes and other particles. J Exp Med. (1971;134:149S-56.
14. Krane SM, Dayer JM, Simon LS, Byrne MS. Mononuclear cell-conditioned medium containing mononuclear cell factor (MCF), homologous with interleukin 1, stimulates collagen and fibronectin synthesis by adherent rheumatoid synovial cells: effects of prostaglandin E2 and indomethacin. Coll Relat Res. (1985;5:99-117.
15. Dumonde DC, Wolstencroft RA, Panayi GS, et al. "Lymphokines": non-antibody mediators of cellular immunity generated by lymphocyte activation. Nature. 1969;224:38-42.